Although androgen receptor signaling is critical for prostate cancer growth and survival, evidence supporting a favorable risk-benefit ratio of androgen deprivation therapy (ADT) is currently limited to men with high-risk or metastatic disease.
This is in part because ADT has been associated with a number of constitutional and somatic side effects, consistent with the widespread tissue expression of sex steroid receptors. ADT is the most common contemporary cause of severe hypogonadism, and men receiving this therapy represent a unique model of severe sex steroid deficiency with a defined time of onset. This review will present an update on the role of ADT in the treatment of prostate cancer, will summarize recent evidence regarding ADT-associated adverse effects with particular emphasis on cardiometabolic and musculoskeletal health, and will provide recommendations for further research.
Written by:
Grossmann M, Cheung AS, Zajac JD. Are you the author?
Dept. of Medicine, Austin Health, University of Melbourne, Victoria, Australia; Dept. of Endocrinology, Austin Health, Victoria, Australia.
Reference: Best Pract Res Clin Endocrinol Metab. 2013 Aug;27(4):603-16.
doi: 10.1016/j.beem.2013.05.001
PubMed Abstract
PMID: 24054933
UroToday.com Prostate Cancer Section
